Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)’s share price fell 5% on Tuesday . The stock traded as low as $6.63 and last traded at $6.79. 2,041,821 shares were traded during mid-day trading, an increase of 76% from the average session volume of 1,157,640 shares. The stock had previously closed at $7.15.

A number of equities analysts have recently commented on the stock. Stifel Nicolaus upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price objective for the company from $8.00 to $15.00 in a research report on Wednesday, July 26th. HC Wainwright assumed coverage on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They issued a “buy” rating and a $15.00 price objective for the company. BMO Capital Markets restated a “buy” rating and issued a $12.00 price objective on shares of Tetraphase Pharmaceuticals in a research report on Monday, May 15th. Zacks Investment Research lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th. Finally, BidaskClub upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $11.21.

The company’s 50-day moving average price is $6.41 and its 200-day moving average price is $7.22. The stock’s market capitalization is $347.16 million.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by $0.07. The firm had revenue of $1.59 million for the quarter, compared to the consensus estimate of $1.54 million. Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. The firm’s revenue was up 28.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.47) earnings per share. Equities research analysts predict that Tetraphase Pharmaceuticals, Inc. will post ($2.54) EPS for the current fiscal year.

In other news, insider Jacques Dumas sold 17,500 shares of the stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $6.00, for a total transaction of $105,000.00. Following the completion of the transaction, the insider now directly owns 17,500 shares in the company, valued at approximately $105,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.50% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. UBS Group AG boosted its position in shares of Tetraphase Pharmaceuticals by 2.3% during the 1st quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 387 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Tetraphase Pharmaceuticals by 0.7% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 129,681 shares of the biopharmaceutical company’s stock valued at $925,000 after acquiring an additional 874 shares during the last quarter. Teza Capital Management LLC boosted its position in shares of Tetraphase Pharmaceuticals by 8.9% during the 1st quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 1,281 shares during the last quarter. American International Group Inc. boosted its position in shares of Tetraphase Pharmaceuticals by 7.1% during the 1st quarter. American International Group Inc. now owns 22,390 shares of the biopharmaceutical company’s stock valued at $206,000 after acquiring an additional 1,486 shares during the last quarter. Finally, Citadel Advisors LLC boosted its position in shares of Tetraphase Pharmaceuticals by 18.6% during the 1st quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock valued at $146,000 after acquiring an additional 2,496 shares during the last quarter. Hedge funds and other institutional investors own 41.73% of the company’s stock.

WARNING: “Tetraphase Pharmaceuticals, Inc. (TTPH) Trading Down 5%” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/09/07/tetraphase-pharmaceuticals-inc-ttph-trading-down-5.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.